“…The PCR primers were designed to amplify PRL 177 (5 -CTATAGACAGGGTTCTCGCG-3 , forward; 5 -GCAGGACAGCAGTTTGGTAA-3 , reverse), PRL 188 (5 -GTCAGATTTGATGTCCCTGG-3 , forward; 5 -GCAGGACAGCAGAAAGTTGA-3 , reverse), GH (5 -CAGCTGTCGGTTGTGTGTTT-3 , forward; 5 -CAGCAGCAAGATTCCCGTTT-3 , reverse), IGF-I (5 -ATAAACCAACAGGCTATGGC-3 , forward; 5 -TTCTGGTGGACTTCCTTGA-3 , reverse), PRL-R (5 -CAGAGATCAAATGCCGTTCTCC-3 , forward; 5 -ATTTCAGGCAGCCGTCATGATC-3 , reverse), and -actin (5 -CATGAAGTGCGACGTTGACA-3 , forward; 5 -CACATCTGCTGGAAGGTGGA-3 , reverse) based on Swennen et al (1992), Reinecke et al (1997), Chen et al (1998), Sekkali et al (1999), Shiraishi et al (1999), Takeuchi (2000) and N R Staten (personal communication). After DNase treatment, RT-PCR was performed with an Access RT-PCR System (Promega Corporation, Madison, WI, USA), BcaBEST RNA PCR Kit version 1·1 (Takara, Tokyo, Japan) and AmpliTaqGold DNA Polymerase (Roche Molecular Systems, Branchburg, NJ, USA) using a PTC-200 Peltier Thermal Cycler (MJ Research Inc., Waltham, MA, USA) and a GeneAmp 2400 PCR System (Perkin Elmer, Norwalk, CT, USA).…”